YS ON 001
Alternative Names: PIKA YS-ON-001; Polyinosinic-polycytidylic acid/inactivated rabies virus; Yivyka; YS-ON-001Latest Information Update: 28 Mar 2025
At a glance
- Originator Yisheng Biopharma
- Developer LakeShore Biopharma
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action B cell stimulants; Cytokine stimulants; Dendritic cell stimulants; Immunostimulants; Macrophage modulators; Natural killer cell stimulants; Regulatory T-lymphocyte inhibitors; Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Solid tumours
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (IM, Injection)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Singapore (IM, Injection)
- 24 May 2024 YS Biopharma is now called LakeShore Biopharma